Analysts Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) PT at $20.33

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have received an average recommendation of “Moderate Buy” from the seven research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $20.3333.

A number of research analysts have issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Wednesday, January 21st. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, February 10th. Finally, JPMorgan Chase & Co. started coverage on shares of Enanta Pharmaceuticals in a report on Friday, November 14th. They issued an “overweight” rating and a $17.00 target price on the stock.

Enanta Pharmaceuticals Stock Up 0.1%

Enanta Pharmaceuticals stock opened at $13.85 on Thursday. The stock has a market capitalization of $401.93 million, a price-to-earnings ratio of -4.33 and a beta of 0.98. The stock has a 50-day simple moving average of $14.09 and a 200 day simple moving average of $11.49. Enanta Pharmaceuticals has a 12-month low of $4.09 and a 12-month high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, February 9th. The biotechnology company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.12. The company had revenue of $18.62 million during the quarter, compared to the consensus estimate of $16.14 million. Enanta Pharmaceuticals had a negative net margin of 106.80% and a negative return on equity of 78.58%. As a group, sell-side analysts anticipate that Enanta Pharmaceuticals will post -4.65 EPS for the current year.

Insider Activity at Enanta Pharmaceuticals

In related news, insider Tara Lynn Kieffer sold 2,106 shares of the firm’s stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $14.23, for a total value of $29,968.38. Following the sale, the insider directly owned 30,620 shares in the company, valued at $435,722.60. This trade represents a 6.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jay R. Luly sold 4,743 shares of the stock in a transaction on Friday, December 5th. The shares were sold at an average price of $14.23, for a total value of $67,492.89. Following the completion of the sale, the chief executive officer owned 858,026 shares of the company’s stock, valued at $12,209,709.98. The trade was a 0.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 11,961 shares of company stock valued at $170,149. Corporate insiders own 11.48% of the company’s stock.

Institutional Trading of Enanta Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. Deutsche Bank AG lifted its stake in shares of Enanta Pharmaceuticals by 4.6% during the 4th quarter. Deutsche Bank AG now owns 24,107 shares of the biotechnology company’s stock valued at $380,000 after buying an additional 1,055 shares in the last quarter. Public Employees Retirement System of Ohio grew its holdings in Enanta Pharmaceuticals by 8.3% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 14,412 shares of the biotechnology company’s stock worth $173,000 after acquiring an additional 1,100 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in Enanta Pharmaceuticals by 8.3% in the third quarter. Ameriprise Financial Inc. now owns 18,007 shares of the biotechnology company’s stock worth $216,000 after purchasing an additional 1,383 shares in the last quarter. AlphaQuest LLC increased its position in Enanta Pharmaceuticals by 18.1% during the 3rd quarter. AlphaQuest LLC now owns 10,198 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 1,562 shares in the last quarter. Finally, Sio Capital Management LLC grew its stake in Enanta Pharmaceuticals by 1.0% during the 2nd quarter. Sio Capital Management LLC now owns 178,774 shares of the biotechnology company’s stock valued at $1,352,000 after purchasing an additional 1,770 shares during the last quarter. 94.99% of the stock is owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals News Summary

Here are the key news stories impacting Enanta Pharmaceuticals this week:

• Positive Sentiment: Zacks upgraded ENTA to a Rank #2 (Buy), calling out improved earnings prospects — a catalyst that can drive near-term buying interest. What Makes Enanta Pharmaceuticals (ENTA) a New Buy Stock
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating with a $20 price target, which supports upside expectations versus the current trading level and can attract momentum buyers. Enanta Pharmaceuticals’ (ENTA) Buy Rating Reiterated at HC Wainwright
• Positive Sentiment: HC Wainwright raised several forward-year EPS estimates (FY2027–FY2030 and quarters Q2/Q3 2026 modestly), indicating slightly improved longer-term profitability assumptions from the same analyst team. These upward tweaks, combined with the maintained Buy rating and $20 target, are constructive for sentiment. MarketBeat: Enanta – HC Wainwright Estimate Changes
• Neutral Sentiment: Reports show a large “increase” in short interest but the data reads as 0 shares with NaN changes and a 0.0 days short-interest ratio — likely a reporting anomaly and not an active short-selling signal. Investors should treat this as non-informative until clarified.
• Negative Sentiment: HC Wainwright lowered its Q4 2026 EPS estimate to ($0.73) from ($0.56), a near-term earnings deterioration that could weigh on sentiment for the upcoming quarter despite the firm’s overall Buy stance. MarketBeat: Enanta – HC Wainwright Lowers Q4 2026 Estimate

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.